n=10 trials

Ten participants test one hypothesis. Results come fast, in weeks instead of years. You contribute to real science while earning rewards and ownership stakes.

Real-world proof: Bryan Johnson's N=1 longevity trials generated hundreds of millions in value through deeply personalized interventions. Our N=10 approach scales this precision while maintaining speed.

Every trial enriches a shared knowledge graph. BiomeAI scans across studies, spots patterns and makes connections humans miss. The system generates personal recommendations, population-level insights, and new hypotheses ready for the next round of testing.

Validated insights don't stay on paper. They move on chain as:

• Compound Tokens funding promising treatments on Pump.science

• Prediction Markets staking on outcomes

• IP Tokens give participatory rights in discoveries through platforms like Molecule

This creates a direct bridge from raw data to tradable value and funding to further validate the hypothesis.

The strongest hypotheses scale into new IP, products, or therapies. These require fresh Biome Keys and new trials of larger scale n=100, pulling discoveries back into the flywheel.